Swiss drugmaker Santhera had licensed the commercial rights for the manufacturing and supply of the drug, branded as Agamree, in North America to Catalyst for an upfront payment of $75 million and an equity investment of $15 million in the company. The U.S. Food and Drug Administration's (FDA) approval comes just months after the approval of Sarepta Therapeutics' Elevidys, the first gene therapy for DMD. DMD, a rare muscle-wasting disorder, is estimated to affect one in 3,500 male births worldwide Santhera's drug works in a similar manner as corticosteroids like prednisone, which are the standard of care for Duschenne patients, but without the same safety concerns such as excessive weight gain and hair growth.